Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 18, 2015 10:19 AM ET


Company Overview of Visterra, Inc.

Company Overview

Visterra, Inc. operates as a biotechnology company. It uses its atomic interaction network analysis to identify disease targets and design therapeutics. The company focuses on therapeutics for infectious diseases and its antibody product candidate, VIS410, a human monoclonal antibody for the prevention and treatment of seasonal and pandemic influenza. It also develops dengue antibody programs; and has a drug development program for an antibody to treat four strains of dengue virus. In addition, it focuses on research programs for infectious and non-infectious diseases; and other collaborative programs. Visterra, Inc. was formerly known as Parasol Therapeutics, Inc. and changed its name to Vi...

One Kendall Square

Suite B3301

Cambridge, MA 02139

United States

Founded in 2007





Key Executives for Visterra, Inc.

Chief Executive Officer, President and Director
Age: 55
Founder and Director
Age: 49
Chief Financial Officer and Chief Operating Officer
Age: 53
Chief Medical Officer
Vice President of Legal
Compensation as of Fiscal Year 2014.

Visterra, Inc. Key Developments

Visterra Announces Additions to its Management Team and Board of Directors

Visterra, Inc. announced two key additions to the company's executive management team and board of directors. José M. Trevejo, MD, PhD, has been appointed Vice President of Development and Akshay Vaishnaw, MD, PhD, of Alnylam Pharmaceuticals, Inc. has been elected to the company's board of directors. In his role as Vice President of Development, Dr. Trevejo will oversee all preclinical and clinical development, as well as regulatory affairs for the company. This includes advancing clinical programs for product candidates from Visterra's pipeline of novel monoclonal antibodies that target infectious diseases, including advancing VIS410 for seasonal and pandemic influenza into phase 2 clinical studies and progressing VIS513 for dengue fever into the clinic. Prior to joining Visterra, Dr. Trevejo served as Medical Director at Genentech, Inc. Dr. Vaishnaw is currently Executive Vice President and Chief Medical Officer of Alnylam Pharmaceuticals, Inc., which he joined in 2006.

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.

Visterra Inc. Acquires Exclusive Patent License for Monoclonal Antibodies Against Dengue Virus from Massachusetts Institute of Technology

Visterra Inc. announced that it has secured an exclusive patent license from Massachusetts Institute of Technology (MIT) to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.

Similar Private Companies By Industry

Company Name Region
DX Biosciences, Inc. United States
Numerate, Inc. United States
Targetech Inc. United States
N-Gene Research Laboratories, Inc. United States
HemoShear, LLC United States

Recent Private Companies Transactions

Private Placement
October 2, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Visterra, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at